These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
424 related articles for article (PubMed ID: 9878048)
21. Tangeretin regulates platelet function through inhibition of phosphoinositide 3-kinase and cyclic nucleotide signaling. Vaiyapuri S; Ali MS; Moraes LA; Sage T; Lewis KR; Jones CI; Gibbins JM Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2740-9. PubMed ID: 24135020 [TBL] [Abstract][Full Text] [Related]
22. IRAG is essential for relaxation of receptor-triggered smooth muscle contraction by cGMP kinase. Geiselhöringer A; Werner M; Sigl K; Smital P; Wörner R; Acheo L; Stieber J; Weinmeister P; Feil R; Feil S; Wegener J; Hofmann F; Schlossmann J EMBO J; 2004 Oct; 23(21):4222-31. PubMed ID: 15483626 [TBL] [Abstract][Full Text] [Related]
23. The nitration of platelet vasodilator stimulated phosphoprotein following exposure to low concentrations of hydrogen peroxide. Sabetkar M; Low SY; Bradley NJ; Jacobs M; Naseem KM; Richard Bruckdorfer K Platelets; 2008 Jun; 19(4):282-92. PubMed ID: 18569864 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of ADP-induced platelet adhesion to immobilised fibrinogen by nitric oxide: evidence for cGMP-independent mechanisms. Oberprieler NG; Roberts W; Graham AM; Homer-Vanniasinkam S; Naseem KM Biochem Pharmacol; 2007 May; 73(10):1593-601. PubMed ID: 17306768 [TBL] [Abstract][Full Text] [Related]
26. Peroxynitrite causes phosphorylation of vasodilator-stimulated phosphoprotein through a PKC dependent mechanism. Aburima A; Riba R; Naseem KM Platelets; 2010; 21(6):421-8. PubMed ID: 20624010 [TBL] [Abstract][Full Text] [Related]
27. Vasodilator-stimulated phosphoprotein regulates proliferation and growth inhibition by nitric oxide in vascular smooth muscle cells. Chen L; Daum G; Chitaley K; Coats SA; Bowen-Pope DF; Eigenthaler M; Thumati NR; Walter U; Clowes AW Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1403-8. PubMed ID: 15178555 [TBL] [Abstract][Full Text] [Related]
28. Antiplatelet effects of caffeic acid due to Ca(2+) mobilizationinhibition via cAMP-dependent inositol-1, 4, 5-trisphosphate receptor phosphorylation. Lee DH; Kim HH; Cho HJ; Bae JS; Yu YB; Park HJ J Atheroscler Thromb; 2014; 21(1):23-37. PubMed ID: 24088646 [TBL] [Abstract][Full Text] [Related]
29. The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents. Russo I; Doronzo G; Mattiello L; De Salve A; Trovati M; Anfossi G Thromb Res; 2004; 114(4):265-73. PubMed ID: 15381390 [TBL] [Abstract][Full Text] [Related]
30. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Pampuch A; Cerletti C; de Gaetano G Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371 [TBL] [Abstract][Full Text] [Related]
31. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eigenthaler M; Nolte C; Halbrügge M; Walter U Eur J Biochem; 1992 Apr; 205(2):471-81. PubMed ID: 1315268 [TBL] [Abstract][Full Text] [Related]
32. Defective smooth muscle regulation in cGMP kinase I-deficient mice. Pfeifer A; Klatt P; Massberg S; Ny L; Sausbier M; Hirneiss C; Wang GX; Korth M; Aszódi A; Andersson KE; Krombach F; Mayerhofer A; Ruth P; Fässler R; Hofmann F EMBO J; 1998 Jun; 17(11):3045-51. PubMed ID: 9606187 [TBL] [Abstract][Full Text] [Related]
33. Cytoskeleton assembly at endothelial cell-cell contacts is regulated by alphaII-spectrin-VASP complexes. Benz PM; Blume C; Moebius J; Oschatz C; Schuh K; Sickmann A; Walter U; Feller SM; Renné T J Cell Biol; 2008 Jan; 180(1):205-19. PubMed ID: 18195108 [TBL] [Abstract][Full Text] [Related]
34. Specific inhibitory effects of the NO donor MAHMA/NONOate on human platelets. Kobsar A; Simonis S; Klinker E; Koessler A; Kuhn S; Boeck M; Koessler J Eur J Pharmacol; 2014 Jul; 735():169-76. PubMed ID: 24780647 [TBL] [Abstract][Full Text] [Related]
35. Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets. Sudo T; Ito H; Kimura Y Platelets; 2003 Sep; 14(6):381-90. PubMed ID: 14602552 [TBL] [Abstract][Full Text] [Related]
36. Mechanism of anti-platelet activity of Oligoporus tephroleucus oligoporin A: involvement of extracellular signal-regulated kinase phosphorylation and cyclic nucleotide elevation. Park JY; Oh WJ; Kim MJ; Kim TH; Cho JY; Park HJ; Lee IK; Kim S; Kim GS; Kim SK; Seo GS; Yun BS; Rhee MH Platelets; 2012; 23(5):376-85. PubMed ID: 22309049 [TBL] [Abstract][Full Text] [Related]
37. Role of cyclic nucleotide-dependent protein kinases and their common substrate VASP in the regulation of human platelets. Walter U; Eigenthaler M; Geiger J; Reinhard M Adv Exp Med Biol; 1993; 344():237-49. PubMed ID: 8209791 [TBL] [Abstract][Full Text] [Related]
38. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors. Glenn JR; White AE; Iyu D; Heptinstall S Platelets; 2012; 23(5):344-51. PubMed ID: 22436052 [TBL] [Abstract][Full Text] [Related]
39. Role of proteins of the Ena/VASP family in actin-based motility of Listeria monocytogenes. Laurent V; Loisel TP; Harbeck B; Wehman A; Gröbe L; Jockusch BM; Wehland J; Gertler FB; Carlier MF J Cell Biol; 1999 Mar; 144(6):1245-58. PubMed ID: 10087267 [TBL] [Abstract][Full Text] [Related]